OrSense (Petach Tikva, Israel) received FDA clearance to bring the company’s NBM 200MP hemoglobin monitor to the U.S., a system that the company hopes will help detect and prevent anemia in hospitalized patients. The device continuously measures hemoglobin (Hb), peripheral oxygen saturation of Hb (SpO2), and it also has low perfusion oximetry, pulse rate, and plethysmography (contraction of the thumb along to the heartbeat).
Alarms can be set to warn clinicians when oxygen saturation or the pulse rate fall outside of preset limits.
More from OrSense about the company’s technology:
OrSense’s devices are based on its proprietary SpectOLightTM technology, which uses an optical measurement platform combined with a ring-shaped sensor that is fitted on the subject’s finger. A gentle pressure is applied by the sensor, temporarily occluding the blood flow in the finger. New blood dynamics are created, generating a unique, strong optical transmission signal, with a high signal-to-noise ratio which is wholly blood specific. During the occlusion, optical elements in the sensor perform a sensitive measurement of the light transmitted through the finger. This method, called Occlusion Spectroscopy, provides a quick, accurate and painless measurement of the subject’s blood constituents.
Product page: NBM 200MP…
Press release: OrSense Receives FDA Clearance for its Noninvasive Hemoglobin Monitor…
